These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 30822212)
1. Combination of static magnetic field and cisplatin in order to reduce drug resistance in cancer cell lines. Jalali A; Zafari J; Jouni FJ; Abdolmaleki P; Shirazi FH; Khodayar MJ Int J Radiat Biol; 2019 Aug; 95(8):1194-1201. PubMed ID: 30822212 [No Abstract] [Full Text] [Related]
2. Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines. Zafari J; Rastegar-Pouyani N; Javani Jouni F; Najjar N; Azarshin SZ; Jafarzadeh E; Abdolmaleki P; Hoseini Shirazi F Sci Rep; 2024 Mar; 14(1):5792. PubMed ID: 38461218 [TBL] [Abstract][Full Text] [Related]
3. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326 [TBL] [Abstract][Full Text] [Related]
4. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression. Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490 [TBL] [Abstract][Full Text] [Related]
5. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous application of cisplatin and static magnetic field enhances oxidative stress in HeLa cell line. Kamalipooya S; Abdolmaleki P; Salemi Z; Javani Jouni F; Zafari J; Soleimani H In Vitro Cell Dev Biol Anim; 2017 Oct; 53(9):783-790. PubMed ID: 28936806 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
8. Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. Pan B; Yao KS; Monia BP; Dean NM; McKay RA; Hamilton TC; O'Dwyer PJ Biochem Pharmacol; 2002 May; 63(9):1699-707. PubMed ID: 12007573 [TBL] [Abstract][Full Text] [Related]
9. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
10. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin. Stehlik P; Paulikova H; Hunakova L Neoplasma; 2010; 57(5):473-81. PubMed ID: 20568902 [TBL] [Abstract][Full Text] [Related]
11. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines]. Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491 [TBL] [Abstract][Full Text] [Related]
12. Relationship between p-cofilin and cisplatin resistance in patients with ovarian cancer and the role of p-cofilin in prognosis. Qin Y; Li W; Long Y; Zhan Z Cancer Biomark; 2019; 24(4):469-475. PubMed ID: 30932883 [TBL] [Abstract][Full Text] [Related]
13. SREBP2 contributes to cisplatin resistance in ovarian cancer cells. Zheng L; Li L; Lu Y; Jiang F; Yang XA Exp Biol Med (Maywood); 2018 Apr; 243(7):655-662. PubMed ID: 29466876 [TBL] [Abstract][Full Text] [Related]
14. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764 [TBL] [Abstract][Full Text] [Related]
15. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression. Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913 [TBL] [Abstract][Full Text] [Related]
17. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models. Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135 [TBL] [Abstract][Full Text] [Related]
19. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776 [TBL] [Abstract][Full Text] [Related]
20. Electrochemical monitoring of anticancer compounds on the human ovarian carcinoma cell line A2780 and its adriamycin- and Cisplatin-resistant variants. Woolley DE; Tetlow LC; Adlam DJ; Gearey D; Eden RD; Ward TH; Allen TD Exp Cell Res; 2002 Feb; 273(1):65-72. PubMed ID: 11795947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]